TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00987272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% Vehicle
Description: Inactive ingredients used as placebo comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine 0.1% Vehicle
Description: Inactive ingredients used as placebo comparator
Study: NCT02915432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 mg/kg anti-PD-1 mAb JS001 Q2W
Description: This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 360 mg anti-PD-1 mAb JS001 Q3W
Description: Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 240mg anti-PD-1 mAb JS001 Q3W
Description: Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
Study: NCT03936192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine sulphate 1500mg and meloxicam 15mg
Description: glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg
Description: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo administered once daily for 12 weeks.
Study: NCT01786876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled SPD557
Description: A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
Study: NCT01141972

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml \[≥75 nmol/L\]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
Study: NCT03597087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia before transurethral resection of the bladder tumor
Description: General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia before transurethral resection of the bladder tumor
Description: General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: General anaesthesia : propopol~Spinal anaesthesia : bupibacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: General anaesthesia : propopol~Spinal anaesthesia : bupibacaine
Study: NCT02220959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walk test
Description: patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
Study: NCT01193205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training
Description: 20 weeks of Dialectical Behaviour Therapy Skills Training
Study: NCT02282254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overnight intervention
Description: Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overnight intervention
Description: Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
Study: NCT02374736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Privigen (Human normal immunoglobulin G (IgG > 98 % purity))
Description: Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL.
Study: NCT01072045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
Study: NCT04288648

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound examination
Description: ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound examination
Description: ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.
Study: NCT03372694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Training
Description: Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM
Description: four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
Study: NCT00975481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Description: Oral tablet; 20 mg dimebon, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Description: Oral tablet; 40 mg dimebon, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Description: Oral tablet; 60 mg dimebon, single dose
Study: NCT02098733

Intervention type: DRUG
Intervention: Pioglitazone/glimepiride
Description: Pioglitazone/glimepiride combination tablets
Study: NCT03500172

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICM
Description: Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICM
Description: Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
Study: NCT02240849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional pillow
Description: streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo general pillow
Study: NCT00589056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT06363318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Description: In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendicectomy
Description: In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done
Study: NCT00975481

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral tablet or capsule; placebo, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam
Description: Oral capsule; 1 mg alprazolam, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam
Description: Oral capsule; 3 mg alprazolam, single dose
Study: NCT00112593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study: NCT03372694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM
Description: four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation Education
Description: General health education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Education
Description: General health education

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
Study: NCT00579241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound on Temporal Bone
Description: All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
Study: NCT02118766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching vehicle control
Study: NCT04744389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic Machine Perfusion
Description: The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic Machine Perfusion
Description: Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
Study: NCT03872427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat Hydrochloride
Description: Given PO
Study: NCT00112593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic bone marrow or peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO
Study: NCT01349842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 20ml of patient peripherical blood will be collected

Intervention type: OTHER
Group type: OTHER
Intervention: Usual clinical and radiological criteria
Description: Clinical examination, tumoral evaluation
Study: NCT00783263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg
Description: Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: rosuvastatin 10 mg
Description: Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: rosuvastatin 10 mg + ezetimibe 10 mg
Description: Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
Study: NCT02680262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit mailed directly
Description: Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit on demand
Description: Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.~The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Second reminder
Description: The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
Study: NCT02108171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
Study: NCT00783263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: rosuvastatin 20 mg
Description: Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
Study: NCT02117492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cuff Closure
Description: Closure of the vaginal cuff following hysterectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cuff Closure
Description: Closure of the vaginal cuff following hysterectomy.
Study: NCT01742663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Gel 3%
Description: Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solaraze® (diclofenac sodium) Gel 3%
Description: Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Description: Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
Study: NCT02313506

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education session, Fitbit Flex, and remote coaching by a PT
Description: Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Same intervention with a 1 month delay
Description: The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
Study: NCT02258191

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: telemonitoring

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham telemonitoring
Study: NCT04061304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: A non-invasive method of brain stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.